The Journal of Urology · 1988 · 175 citations · 11 references
MedicinePharmacotherapyUrologyAndrologyReproductive SurgeryVoiding DysfunctionErectile DysfunctionPenile PathologySexual DysfunctionDifferential Diagnosis CriteriaErectile Dysfunction ScreeningIntracavernosal Injection TherapyPenile PriapismProstaglandin PharmacologyScreening Test SelectionSystemic Adverse ReactionsVasculogenic Erectile Dysfunction
Intracavernous injection of prostaglandin E1 was used in 210 men as a screening test for the differential diagnosis of vasculogenic impotence. Of these 210 patients 112 entered an autoinjection protocol for treatment of erectile dysfunction. Prostaglandin E1 appears to be effective in the diagnosis and treatment of nonvasculogenic impotence because it is a physiological agent that is metabolized locally within the cavernous tissue. Additionally, in our series neither systemic reactions nor priapism occurred, nor was fibrosis of cavernous tissue or scar formation observed after up to 90 injections.
11
Physiology of Erection and Pharmacological Management of Impotence
Tom F. Lue, Emil A. Tanagho · The Journal of Urology · 1987 · 569 citations
Medicine, Pharmacology, Urology +11
Intracavernous Injection of Papaverine as a Diagnostic and Therapeutic Method in Erectile Failure
R Virag, Dafna Frydman, M. Legman et al. · Angiology · 1984 · 310 citations
Medicine, Pharmacology, Urology +14
Metabolism of prostaglandins A1 and E1 in man.
Michael S. Golub, Priscilla Zia, Mitsuhiro Matsuno et al. · Journal of Clinical Investigation · 1975 · 194 citations · Full text